This article is more than 5 years old. Information may no longer be current.
Lumenis gains FDA approval for updated Selecta laser line
YOKNEAM, Israel — Lumenis recently received U.S. marketing approval for its Selecta family of lasers, the company announced in a press release.
The updated lasers include the Selecta 1064-nm Nd:YAG base platform, designed for anterior segment procedures such as elimination of posterior capsular opacification or creation of peripheral iridotomies. The Selecta Duo adds to the base model Nd:YAG with a 532-nm photocoagulator for posterior segment applications. The Selecta Duet upgrades the base model with a Q-switched, frequency-doubled 532-nm laser for selective laser trabeculoplasty. The Selecta Trio combines the Nd:YAG, diode-pumped solid-state 532-nm photocoagulator and Q-switched, frequency-doubled 532 nm laser.
The Novus 3000 is a “fully-integrated and powerful 532-nm operating room photocoagulator with reliable diode-pumped solid state technology that uses both a touch screen and remote control," according to Lumenis.
Other product approvals include the Lumenis 1000 Integrated Slit Lamp, the Lumenis 950 Slit Lamp and the Coaxial Multicolor Laser Indirect Ophthalmoscope.
The new devices were debuted for the U.S. ophthalmic market during the American Academy of Ophthalmology meeting.